English-language podcasts

Normal Curves: Sexy Science, Serious Statistics

Huntington’s Disease: Can Gene Therapy Slow It Down?

69 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

Could a new gene therapy slow the progression of Huntington’s disease? Early results suggested an astonishing 80% reduction in disease progression. But there’s a catch: the evidence comes from just a handful of treated patients, compared with patients from an entirely different study. How can we know whether we're comparing like with like? We dig into the science behind the treatment, the statistical challenges of finding a fair comparison group, and the heated controversy between the drug company and the FDA. Along the way, we take a statistical detour into propensity score matching—and wrestle with a difficult question: How much evidence should we demand when patients are running out of time? Statistical topics External control groups Randomized controlled trials Sham surgery controls Propensity scores Restricted full propensity score matching Inverse probability of treatment weighting (IPTW) Confounding Selection bias Methodologic Morals “Seventeen patients is still 17 patients, no matter how you cut it and no matter how many controls you have.” “With external controls, the question is always, are we seeing the treatment or are we seeing the difference between the studies?” References uniQure.uniQure announces update on US Phase I/II clinical trial of AMT-130 gene therapy for the treatment of Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-us-phase-iii-clinical-trial-amt-130). June 21, 2023. uniQure.uniQure announces positive interim data update demonstrating slowing of disease progression in Phase I/II trials of AMT-130 for Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating). July 9, 2024. uniQure.uniQure announces positive topline results from pivotal Phase I/II study of AMT-130 in patients with Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii). September 24, 2025. uniQure.Pivotal Phase I/II AMT-130 program update: 36-month analysis (https://www.cureffi.org/media/2025/10/uniqure_slides_2025-09-24.pdf). Investor presentation. September 24, 2025. uniQure announces additional data from ongoing Phase I/II studies of AMT-130 in Huntington’s disease showing continued slowing of disease progression (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies). September 29, 2026. uniQure.Investor presentations and archived webcasts (https://www.uniqure.com/investors-media/events-presentations). uniQure.uniQure announces alignment with FDA on key elements of accelerated approval pathway for AMT-130 in Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated). December 10, 2024. uniQure.uniQure provides regulatory update on AMT-130 for Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0). November 3, 2025. uniQure.uniQure provides regulatory update on AMT-130 for Huntington’s disease (https://www.sec.gov/Archives/edgar/data/1590560/000110465926021890/qure-20260302xex99d2.htm). March 2, 2026. uniQure.uniQure announces plan for BLA submission for AMT-130 in Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons). June 17, 2026. uniQure.uniQure announces FDA acceptance and priority review of the Biologics License Application for ifezuntirgene inilparvovec for the treatment of Huntington’s disease (https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics). November 2, 2026. Feuerstein A.FDA is 'not convinced' UniQure’s Huntington’s therapy has benefit, senior official says (https://www.statnews.com/2026/03/03/uniqure-huntingtons-treatment-fda-official-comments/). STAT. March 3, 2026. Reuters.Senior FDA official calls uniQure’s Huntington’s disease treatment a failure (https://www.reuters.com/business/healthcare-pharmaceuticals/sr-fda-official-calls-uniqures-huntingtons-disease-treatment-failure-2026-03-05/). March 5, 2026. Jewett C.F.D.A. faces upset over denials of new drugs (https://www.nytimes.com/2026/03/05/health/fda-drugs-rare-diseases-rfk-jr.html). New York Times. March 5, 2026. Jackson K.Bring hope to Huntington’s disease families: Urge the FDA to uphold accelerated approval (https://www.change.org/p/bring-hope-to-huntington-s-disease-families-urge-the-fda-to-uphold-accelerated-approval). Change.org. Further notes on Brain Volume (https://www.normalcurves.com/further-notes-on-brain-volume/) Kristin and Regina’s online courses: Demystifying Data: A Modern Approach to Statistical Understanding (https://online.stanford.edu/courses/som-xche0033-demystifying-data-modern-approach-statistical-understanding) Clinical Trials: Design, Strategy, and Analysis (https://online.stanford.edu/courses/som-xche0030-clinical-trials-design-strategy-and-analysis) Medical Statistics Certificate Program (https://online.stanford.edu/programs/medical-statistics-program) Writing in the Sciences (https://www.coursera.org/learn/sciwrite) Epidemiology and Clinical Research Graduate Certificate Program (https://online.stanford.edu/programs/epidemiology-and-clinical-research-graduate-certificate) Program that Kristin teaches in:: Epidemiology and Clinical Research Graduate Certificate Program (https://online.stanford.edu/programs/epidemiology-and-clinical-research-graduate-certificate) Kristin’s manuscript writing course: Find us on: Kristin - LinkedIn (https://www.linkedin.com/in/kristin-sainani-642b5914/) &Twitter/X (https://x.com/KristinSainani) Regina -LinkedIn (https://www.linkedin.com/in/reginanuzzo/) &https://www.reginanuzzo.com/ReginaNuzzo.com (http://reginanuzzo.com/) (00:00) - Cold Open: FDA Demands a Bigger Trial (08:17) - Huntington's Genetics: Dominant Inheritance and CAG Repeats (18:05) - AMT-130: Gene Therapy Delivered by Brain Surgery (20:31) - Early Trials, Sham Surgery, and Safety (26:55) - External Controls: A Statistical Detour (30:04) - Two-Year Headline: 80% Reduction (37:39) - Propensity Scores: Barbie vs. Oppenheimer (50:11) - FD...

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from Normal Curves: Sexy Science, Serious Statistics

Normal Curves: Sexy Science, Serious Statistics

Researching Honesty Part 2: Can innocent mistakes explain the data?

73 min

Does cheating make you more creative? A provocative study from Harvard Business School suggested that it does. But data detectives uncovered suspicious patterns in the results, and a Harvard investigation found even more troubling changes in the data. In Part 2 of our investigation into the Francesca Gino research misconduct case, we dig into the now-retracted “Evil Genius” study and the suspicious changes that made its results look better, then turn to Harvard law professor Lawrence Lessig's defense of Gino: Could innocent mistakes by “an army of research assistants” explain what happened? Along the way, we explore the trap of circular reasoning in statistics, why good data management matters, and how much responsibility researchers bear for their data even when it's out of their hands. Statistical topics Statistical sleuthing Data forensics Data integrity Data cleaning Data management Reproducibility Statistical significance Spreadsheets Predictor variables Outcome variables Circular

Discuss this episode

Community Poll

Companies should be responsible for serious harm caused by suppliers they choose.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

Your neighbor saves a public parking spot with an orange cone. Do you move it?

Street parking is scarce after a snowstorm. Your neighbor spent an hour digging out the space in front of their home and now guards it with an orange cone, even though curb spaces legally belong to everyone. You arrive tired and the cone is blocking the only open spot.

Can effort create a personal claim to something public?

Explore this quandary